Building E, 7th Floor, Room E7.6
21 articles with Confo Therapeutics
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates.
Confo Therapeutics announced the establishment of its Medical Advisory Board. The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain
Confo Therapeutics announced that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship.
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development
Confo Therapeutics announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications.
6/12/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Confo Therapeutics announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director.
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Confo Therapeutics announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer effective June 1, 2020.
Confo Therapeutics, a pioneering biopharma company, announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”.
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH announce a drug discovery collaboration on an undisclosed G-protein coupled receptor.
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors
3/1/2019Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.
Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology
Confo Therapeutics today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.
12/10/2018Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
Confo Therapeutics today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019.
Confo Therapeutics announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed GPCR for the treatment of neurological and developmental disorders.